Reg reform bill's risk assessment exemption provisions called inadequate by FDA.
This article was originally published in The Tan Sheet
Executive Summary
FDA DEEMS S 343's RISK ASSESSMENT EXEMPTION FOR HEALTH THREATS INADEQUATE to "permit the agency to take expeditious action to avert harm." In an analysis of a revised version of the "Comprehensive Regulatory Reform Act" supported by Senate Majority Leader Robert Dole (R-Kan.) and Sen. Bennett Johnston (D-La.), FDA asserted that the exemption from conducting risk assessments for "likely health and safety threats" would not allow timely FDA actions.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning